To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Summary of Baxter International 2026 Conference Call Company Overview - **Company**: Baxter International (NYSE: BAX) - **Date of Conference**: February 26, 2026 Key Industry Insights - **Medtech Fundamentals**: The underlying fundamentals of the medtech industry are described as solid and stable, despite stock performance concerns. Patient volumes and procedure volumes are in a decent place, with no significant hyperinflationary pressures noted [12][13]. - **IV Solutions Market**: Demand for IV solutions has decreased by approximately 10-15% from pre-hurricane levels, establishing a new baseline for the market. This decline is attributed to changes in clinical practices following a hurricane [13][14][41]. Company-Specific Developments - **Leadership Changes**: The arrival of a new CEO, Andrew, is seen as timely for Baxter, allowing the company to build on a clearer operational foundation after recent distractions from divestitures [20][21]. - **Operational Model**: The introduction of a new operating model (GPS) aims to enhance consistency in operations and performance tracking. This model is expected to lead to improved operational predictability [22]. - **Verticalization Strategy**: Baxter is evolving its business structure to allow for end-to-end ownership of profit and loss (P&L), moving away from a country-led structure. This change is intended to streamline decision-making and improve accountability [29][30][37]. Financial Performance and Guidance - **2026 Guidance**: The guidance for 2026 is described as prudent, factoring in challenges and opportunities. It does not include any sales from the Novum product, which is under a voluntary shipping hold [101][103]. - **Margin Expectations**: The company anticipates sequential improvement in gross and operating margins throughout 2026, particularly in the second half of the year, as operational issues are resolved [116][118]. - **Capital Allocation**: Baxter is focused on deleveraging its balance sheet, targeting a debt-to-EBITDA ratio of three times by the end of the year. Internal investments in R&D and capital spending remain a priority [131][134]. Product Innovations - **New Products**: The Connex 360, a next-generation monitoring device, and the Dynamo, a connected stretcher, are highlighted as key innovations expected to drive growth in 2026. Customer feedback has been positive for these products [76][78]. Challenges and Risks - **Supply Chain Issues**: The company has faced supply challenges in its pharmaceutical business, which have impacted production and market performance. These issues are expected to improve in the second half of 2026 [47][110]. - **Tariff Changes**: Uncertainty surrounding tariff changes is acknowledged, with ongoing efforts to assess their impact on the business [99][100]. Conclusion - Baxter International is positioned at a pivotal point, focusing on stabilizing operations, improving financial performance, and driving innovation. The company aims to build credibility with stakeholders through consistent execution and strategic growth initiatives as it moves into 2026 [145][151].

Core Insights - The Artisan Value Income Fund achieved a return of 2.21% in Q4 2025 and finished the year with a total return of 10.03% for the investor class [5] - Over the past three years, the portfolio has generated an approximate annualized return of 10% [5] Performance Summary - The portfolio's Q4 return was 2.21% [5] - The total return for the year was 10.03% for the investor class [5] - The annualized return over the last three years is around 10% [5]

Core Viewpoint - Baxter International Inc. is facing challenges in financial performance despite reporting strong sales growth, leading to a negative market reaction and a cautious outlook for 2026 [2][5][6] Financial Performance - Baxter reported fourth-quarter sales of $2.974 billion, an 8% increase year over year, exceeding the consensus estimate of $2.824 billion [3][6] - The adjusted earnings per share (EPS) for the quarter was 44 cents, which fell short of management's guidance and Wall Street expectations due to an unfavorable product mix [2][6] - The adjusted gross margin contracted by 900 basis points to 35.5%, and operating income decreased by 16% year over year [4] Market Reaction - Following the earnings report, Baxter's stock price declined by 12.5%, reflecting investor concerns over the company's performance [4] - The stock is currently priced at $18.71, representing a decrease of 15.99% over the past year [5] Future Outlook - Baxter's guidance for 2026 indicates flat sales growth or a slight increase of just 1%, with EPS projected between $1.85 and $2.05, which is below consensus estimates [5][6] - Ongoing disruptions at a crucial manufacturing unit are contributing to the negative outlook and market reaction [5]

Core Insights - Baxter International Inc. shares experienced a 15% decline intra-day following the release of fourth-quarter earnings that fell short of expectations and a weaker-than-anticipated guidance for 2026 [1] Financial Performance - The company reported adjusted EPS of $0.44, which was below analyst estimates of $0.54 [2] - Revenue reached $2.97 billion, surpassing the consensus estimate of $2.84 billion, marking an 8% increase on a reported basis and a 3% operational growth compared to the previous year [2] - Despite the revenue exceeding expectations, concerns regarding profitability negatively impacted investor sentiment [2] Future Guidance - Baxter projected fiscal 2026 adjusted EPS to be in the range of $1.85 to $2.05, significantly lower than the analyst consensus of $2.25 [2] Operational Challenges - President and CEO Andrew Hider acknowledged that while sales growth was achieved across all segments, the fourth-quarter performance did not meet internal expectations, highlighting the company's focus on operational improvements [3] - The company reported a U.S. GAAP net loss from continuing operations of $2.01 per diluted share, which included a $485 million goodwill impairment charge related to its Front Line Care reporting unit and a $330 million valuation allowance on U.S. deferred tax assets [3] Segment Performance - Medical Products & Therapies revenue increased by 6% to $1.39 billion [4] - Healthcare Systems & Technologies revenue rose by 5% to $827 million [4] - Pharmaceuticals revenue grew by 4% to $668 million [4]

Research and Development - R&D expenditures were $518 million in 2025, $590 million in 2024, and $518 million in 2023, focusing on enhancing future growth through clinical differentiation [43]. - The company aims to create a more resilient supply chain and align its manufacturing footprint with commercial activities, potentially consolidating R&D facilities [43]. Workforce and Employee Engagement - The company employed approximately 37,500 people globally as of December 31, 2025, with 15,100 employees in the United States and 22,400 employees outside the United States [52]. - Recruitment efforts include a tuition reimbursement program and an e-learning platform, BaxU, to foster a growth mindset among employees [55]. - The company conducts anonymous surveys to assess employee feedback on leadership confidence, compensation competitiveness, and career growth opportunities [55]. - The results of employee engagement surveys are reviewed by senior leaders and shared with the Board of Directors [55]. - The company is committed to improving its human resources programs based on survey feedback from its global workforce [55]. - The company emphasizes a zero-harm workplace and is focused on employee engagement and safety controls for high hazard work activities [55]. - The company’s compensation programs are designed to align employee compensation with performance, balancing short-term and long-term incentives [55]. Business Strategy and Portfolio Management - The company is actively managing its portfolio through acquisitions and divestitures, including the divestiture of its Kidney Care business [32]. - The company has established purchasing agreements with several major Group Purchasing Organizations (GPOs) in the United States, which are subject to renewal [34]. Regulatory and Legal Environment - The company is subject to extensive regulation by various government agencies, including the FDA and EMA, impacting product testing, safety, and marketing [49]. - The company is involved in ongoing patent litigation, which can result in significant financial implications and affect product sales [42]. - The company faces risks related to patent protection and potential litigation that could impact competitiveness and business prospects [334]. Financial Performance and Market Conditions - The company has decreased its quarterly dividend to $0.01 per share and cannot guarantee future increases or continuity in dividend payments [334]. - The company’s stock price has experienced significant fluctuations and may continue to do so [334]. - Changes in tax laws may negatively affect the company's operating results [334]. Competition and Market Position - The company faces substantial competition in each of its segments from both international and domestic healthcare and medical product companies [38]. Sustainability and Corporate Responsibility - The company is focused on sustainability and corporate responsibility, with a 2030 Corporate Responsibility Commitment anchored by three strategic goals [48].

分组1 - Baxter International Inc. experienced a significant decline in share price following disappointing Q4 results and a negative FY 2026 guidance [1] - The company's current market capitalization stands at $9.6 billion, and it is trading with a single-digit price-to-earnings ratio, indicating potential undervaluation [1] 分组2 - The healthcare equipment industry is facing challenges, as evidenced by Baxter's recent performance, which may reflect broader market trends [1]

Core Viewpoint - Baxter International Inc. experienced a significant decline in share price following disappointing Q4 results and a negative FY 2026 guidance, indicating potential challenges ahead for the company in the Healthcare Equipment industry [1]. Financial Performance - The company's market capitalization is currently $9.6 billion, reflecting a downturn in investor confidence [1]. - Baxter's stock is trading at a single-digit price-to-earnings ratio, suggesting that the market may be undervaluing the company or anticipating further difficulties [1]. Future Outlook - The FY 2026 guidance provided by Baxter is described as "ugly," which raises concerns about the company's growth prospects and operational performance in the coming years [1].

Core Insights - Baxter reported a fourth-quarter adjusted EPS of 44 cents, which was below management guidance of 52-57 cents and Wall Street estimate of 54 cents, primarily due to an unfavorable product mix [1] - The company achieved sales of $2.974 billion, representing an 8% year-over-year increase on a reported basis and a 3% increase on an operational basis, surpassing the consensus estimate of $2.824 billion [1] Sales Performance - Medical Products & Therapies segment sales were approximately $1.39 billion, increasing by 6% on a reported basis and 4% on an operational basis, driven by higher sales in the Infusion Therapies & Technologies division and strong global demand for Advanced Surgery products [3] - Healthcare Systems & Technologies segment sales reached $827 million, up 5% on a reported basis and 4% on an operational basis, reflecting demand for Care & Connectivity Solutions products and growth in the Front Line Care division [4] - Pharmaceutical sales totaled approximately $668 million, an increase of 4% on a reported basis and 2% on an operational basis, with continued strength in Drug Compounding partially offset by reduced sales in Injectables & Anesthesia [4] Management Commentary - The CEO emphasized that while sales growth was achieved across all segments, the fourth-quarter results did not meet expectations, highlighting the need for continuous improvement and the introduction of a new operating model aimed at simplifying the organization and enhancing performance [5] Future Guidance - Baxter expects fiscal 2026 adjusted earnings to be between $1.85-$2.05 per share, compared to the consensus of $2.25, with an adjusted operating margin projected between 13%-14% [6] - The company forecasts 2026 sales to be between $11.24 billion and $11.36 billion, slightly below the consensus of $11.31 billion, with expected sales growth flat to an increase of 1% [6] Stock Performance - Baxter shares were down 15.6% at $18.79 at the time of publication, trading near its 52-week low of $17.4 [7]

Core Insights - Baxter International Inc. reported fourth-quarter 2025 adjusted earnings per share (EPS) of 44 cents, missing the Zacks Consensus Estimate of 53 cents by 17% and declining 24% from the previous year [1][7] - On a GAAP basis, the company reported a loss per share of $2.19 compared to a loss of 95 cents in the prior-year quarter [1] Revenue Performance - Revenues from continuing operations totaled $2.97 billion, reflecting an 8% increase on a reported basis and a 3% increase on an operational basis, surpassing the Zacks Consensus Estimate by 6.5% [3] - U.S. sales from continuing operations were $1.55 billion, up 3% on a reported basis but down 1% on an operational basis [3] - International sales from continuing operations reached $1.42 billion, showing a 14% increase on a reported basis and an 8% increase on an operational basis [3] Segment Analysis - Medical Products & Therapies segment sales totaled $1.39 billion, up 6% reported and 4% operationally, driven by strong demand in Infusion Therapies & Technologies and Advanced Surgery products [5] - Infusion Therapies and Technologies sales were $1.06 billion, up 4% year over year reported and 1% operationally [8] - Healthcare Systems and Technologies segment sales were $827 million, up 5% year over year reported and 4% operationally [9] - Pharmaceuticals segment sales were $668 million, up 4% year over year reported and 2% operationally, with growth driven by Drug Compounding [10] Margin and Expense Analysis - Adjusted gross profit was $1.06 billion, down 13.9% year over year, with adjusted gross margin contracting 900 basis points to 35.5% [11] - Adjusted operating income from continuing operations totaled $352 million, down 16% year over year, with adjusted operating margin contracting 340 basis points to 11.8% [12] 2026 Guidance - Baxter expects 2026 sales to be flat to up 1% on a reported basis, with adjusted EPS projected in the range of $1.85-$2.05, below the Zacks Consensus Estimate of $2.33 [13]